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De Backer I, Hussain SS, Bloom SR, Gardiner JV. Insights into the role of
neuronal glucokinase. Am J Physiol Endocrinol Metab 311: E42–E55, 2016. First
published May 17, 2016; doi:10.1152/ajpendo.00034.2016.—Glucokinase is a key
component of the neuronal glucose-sensing mechanism and is expressed in brain
regions that control a range of homeostatic processes. In this review, we detail
recently identified roles for neuronal glucokinase in glucose homeostasis and
counterregulatory responses to hypoglycemia and in regulating appetite. We de-
scribe clinical implications from these advances in our knowledge, especially for
developing novel treatments for diabetes and obesity. Further research required to
extend our knowledge and help our efforts to tackle the diabetes and obesity
epidemics is suggested.
glucokinase; glucose sensing; glucose homeostasis; appetite; counterregulatory
response; neuronal
BACKGROUND: GLUCOKINASE FUNCTION AND EXPRESSION
Glucose-Sensing Neurons
GLUCOSE IS A PRIMARY FUEL SOURCE for the central nervous
system (CNS) and is important for normal neuronal function
(8). Neuronal glucose-sensing mechanisms allow the brain to
constantly monitor neuronal glucose levels to control periph-
eral metabolic functions involved in energy and glucose ho-
meostasis (87).
Glucose acts as a signaling molecule as well as an energy
substrate in glucose-sensitive neurons. Two types exist: glu-
cose-excited (GE) and glucose-inhibited (GI) neurons. Both
GE and GI neurons are typically found in glucose-sensing
brain regions such as the hypothalamus or brainstem (Table 1)
(25, 73, 74, 167). The firing rate of GE neurons increases and
that of GI neurons decreases as ambient glucose levels rise
(42). Current evidence suggests that the majority of GE neu-
rons express anorexigenic peptides, whereas GI neurons re-
lease appetite-stimulating peptides during hypoglycemic states
to increase feeding (66, 109).
Glucokinase in the Periphery
Glucokinase, also known as hexokinase IV, catalyses the
conversion of glucose to glucose-6-phosphate, which consti-
tutes the first step of glycolysis. In most cells, it is catalyzed by
hexokinase I. Glucokinase has certain biochemical properties
that differentiate it from other hexokinases and allow it to
function as a glucose-sensing enzyme (89). It has a lower
affinity for glucose than other hexokinases (Km 10 mmol/l)
and is not saturated at physiological glucose concentrations.
Unlike other hexokinases, glucokinase is not inhibited by the
product of the reaction it catalyzes. These properties allow the
rate of glucose phosphorylation to be dependent on and pro-
portional to intracellular glucose levels (95).
Glucokinase is expressed in the liver and pancreas (68, 159).
It exists as two different isoforms with the same kinetic
properties but different functions (67). These isoforms are
encoded by the same gene, but separate promoters lead to
different splicing patterns, producing different variants of the
glucokinase enzyme (135). The function of glucokinase in the
pancreas is well established. Pancreatic glucokinase is in-
volved in the process of glucose-stimulated insulin secretion
(GSIS). It plays a key role in sensing alterations in glucose
levels and triggering insulin release. A rise in glucose concen-
tration results in increased cellular adenosine triphosphate
(ATP) production, causing the closure of ATP-sensitive potas-
sium (KATP) channels and the depolarization of the -cell.
Calcium (Ca2) influx through voltage-gated Ca2 channels
ensues (73, 89, 130), leading to insulin release. In the liver,
glucokinase has a central role in promoting the uptake of
glucose and its subsequent conversion to glycogen for energy
storage (45, 114, 130, 159). Mutations in the glucokinase gene
lead to abnormalities in glucose homeostasis in rodents and
humans, whereas abnormalities in glucokinase function in the
pancreas and liver have been implicated in diabetes mellitus
(13, 117).
Neuronal Glucokinase
The expression of glucokinase mRNA and protein has been
demonstrated in multiple neuronal populations in the CNS in
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rats (Fig. 1), mice, and humans (2, 22, 42, 59, 90, 92, 93, 134,
135). Glucokinase is expressed in numerous hypothalamic
nuclei, including the arcuate nucleus (ARC), ventromedial
nucleus (VMN), and lateral hypothalamic area (LHA) (90, 92,
111). Glucokinase mRNA has also been detected in the para-
ventricular nucleus (PVN) and dorsomedial nucleus (DMN),
although very little is known about its function in these nuclei.
Outside of the hypothalamus glucokinase has been identified in
the medial amygdalar nucleus (MAN) (92). It was also found
in the three nuclei that make up the dorsal vagal complex
(DVC) of the brainstem, the nucleus tractus solitarius (NTS),
the area postrema (AP), and the dorsal motor nucleus of the
vagus (DMV). All DVC nuclei play an important part in
regulating homeostatic processes (Fig. 1) (42, 90). Glucokinase
is also expressed in glial cells such as hypothalamic tanycytes
(46, 139). Glucokinase in these cells is thought to have an
important role in energy homeostasis; however, this review
will focus on neuronal glucokinase.
Neuronal glucokinase mRNA has a splicing pattern similar
to the pancreatic isoform, suggesting that it has a similar role
to the pancreatic isoform (135, 139). The neuronal form of the
enzyme is thought to play a central role in glucose sensing in
GE neurons (6, 69, 73) via a mechanism comparable with that
of glucokinase in pancreatic -cells (Fig. 2) (42). In keeping
with this, the involvement of KATP channels in neuronal
glucose sensing (12, 123) and colocalization of glucokinase
and KATP channels has been demonstrated in several studies
(92, 161).
Glucokinase plays a central role in both GE and GI
glucose-sensing neurons (42, 73, 74). The glucose-sensing
mechanism of GE neurons is similar to that of pancreatic
-cells. As glucose levels rise, glucose enters the neuronal
cell via glucose transporter 2 (GLUT2). There it is phos-
phorylated by glucokinase, increasing the cytosolic ATP/
ADP ratio and causing the closure of KATP channels (12,
60, 89). Neuronal depolarization triggers Ca2 ion entry via
Ca2 channels, leading to neurotransmitter secretion
(Fig. 2) (42, 74).
The mechanism underlying glucose sensing in GI neurons is
less well understood. Calcium imaging studies reveal that
70% of GI neurones in the VMN are affected by GK
inhibitors (42, 73), suggesting that GK is involved in glucose
sensing in GI neurons. Their activity is reduced in the presence
of glucose due to hyperpolarization of the cell. The extent of
GK involvement is unclear, although hyperpolarization has
been proposed to occur via stimulation of Na/K ATPase
pumps caused by a glucokinase-induced rise of ATP levels
within neurons, leading to inhibition of neuronal activity
(Fig. 3) (80). An alternative, glucokinase-independent
mechanism, has also been postulated. GI neurons may
become hyperpolarized following glucose-induced activa-
tion of postsynaptic cystic fibrosis transmembrane regulator
(CFTR) Cl channels (27, 151) via the activation of aden-
osine monophosphate-activated protein kinase (AMPK) and
nitric oxide signaling (110, 151). Further studies are needed
to shed light on this mechanism.
Glucokinase-Independent Glucose Sensing
Neuronal glucose sensing does not rely entirely on glucoki-
nase; non-glucokinase-dependent glucose-sensing mechanisms
also exist. For instance, the cellular energy sensor AMPK is
also involved in this process. In rats, VMN AMPK knockdown
abolished the glucagon response to hypoglycemia, whereas
pharmacological activation of AMPK in the VMN improved
the response to hypoglycaemia (100, 101). AMPK is believed
to enable ventromedial hypothalamic GI neurons to depolarize
in response to decreased glucose levels via a mechanism
involving nitrous oxide (NO) and cyclic guanosine monophos-
phate (cGMP) (110), with hyperglycemia having the opposite
effect (29). Another important energy sensor, per-arnt-sim
kinase (PASK), may also play a role in neuronal glucose
sensing. Its expression varies acutely in accord with glucose
levels, and it may be involved in the signaling mechanism of
AMPK-mediated glucose sensing (61, 62). Glucose sensing via
sodium-coupled glucose cotransporter (SGLT) 1–3 has also
been reported (115). The mechanism by which signals from
different metabolites are integrated to generate a net neuronal
output effecting homeostasis and the complex interplay be-
tween neuronal sensors such as SGLTs, AMPK, and PASK
Table 1. The role of glucokinase in different brain regions
Brain Region Role of Glucokinase Mechanism
Type of
Neuron Ref. Nos.
ARC Appetite, particularly for glucose-rich
foods; counterregulatory response to
hypoglycemia
KATP channels NPY;
GHRH? Vagus; Reward?
GI 15, 20, 32, 42-44, 47, 58, 63, 70, 73, 75,
77, 79, 86, 92, 96, 113, 121, 142,
144, 145, 153
LH Appetite: glucoprivic feeding Orexin? Reward? Vagus? GI 38, 56, 74, 77, 86, 92, 94, 113, 142,
147, 153, 171, 176
VMH Glucose homeostasis KATP channels; GABA;
NO; vagus; adrenergic
receptors
GE 16, 17, 23, 30, 40, 42, 50, 51, 58, 63,
73, 75, 81, 82, 88, 98, 99, 116, 141,
154, 155, 165, 172, 177
Counterregulatory response to
hypoglycemia
MAN Glucose homeostasis; counterregulatory
response to hypoglycemia
Vagus? ? 41, 162, 174, 175,
AP Energy homeostasis ? ? 170, 52, 3, 36
NTS Glucose homeostasis KATP channels? ? 2, 37, 42, 84, 92, 158, 173
GLUT2?
DMV Glucose homeostasis KATP channels? ? 2, 92, 126
GI, glucose inhibited; GE, glucose excited; GHRH, growth hormone-releasing hormone; ARC, arcuate nucleus; LH, lateral hypothalamus; VMH, ventromedial
hypothalamus; MAN, medial amygdalar nucleus; AP, area postrema; NTS, nucleus tractus solitarius; DMV, dorsal motor nucleus of the vagus.
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still needs further investigation. It is also important to note that
in glucokinase-expressing neurons, other hexokinases are pres-
ent to produce ATP regardless of variations in extracellular
glucose concentrations.
The Role of Neuronal Glucokinase
The recent insights into the role of glucokinase in glucose-
sensing neurons will be detailed in this review. It builds on
previous work that provides a strong evidence base for its
function in different brain regions and extends the importance
of glucokinase beyond the hypothalamus. An understanding of
this important neuronal metabolic sensor will undoubtedly help
promote our understanding of disease processes and lead to
effective drug development.
GLUCOKINASE AND THE REGULATION OF GLUCOSE
HOMEOSTASIS
The most clearly defined role of neuronal glucokinase is
for the regulation of glucose homeostasis. This appears to be
mediated mainly by glucokinase in the VMH and MAN
through modulation of the counterregulatory response
(CRR). Other mechanisms involving glucokinase in the
DVC may be at play, but this remains to be demonstrated
conclusively.
Glucokinase and the Counterregulatory Response
Studies have shown that glucokinase in the ventromedial
hypothalamus (VMH), VMN, and medial amygdalar nucleus
plays a central role in the CRR, a feedback system to counter-
act hypoglycemia by increasing production of glucose and
limiting its utilization (98). It is characterized by the release of
glucagon, which suppresses the secretion of insulin and aug-
ments gluconeogenesis and glycogenolysis, catecholamines,
and other hormones (4).
Glucokinase in the ventromedial hypothalamus: regulator of
the counterregulatory response to hypoglycemia. The hypo-
thalamus has long been described as an important center for the
regulation of glucose homeostasis (157) as well as for appetite
(32, 96). For more than 40 years, evidence has been generated
demonstrating that it is a center for glucose-sensing (27, 43, 83,
97, 108, 138). Various regions of the hypothalamus express
glucokinase, but to date glucokinase in the ventromedial hy-
pothalamus (VMH) (73) has been the main focus of research
(Fig. 4).
AP
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Fig. 1. Location of main brain centers containing glucokinase-expressing neurons in the rat brain. A: sagittal section diagram illustrating the position of the brain
regions in the rat brain-expressing glucokinase believed to be involved in glucose sensing, which are located mostly in the hypothalamus and in the brainstem.
B: coronal section diagram of glucokinase-expressing nuclei of the brainstem. C: coronal section diagram of glucokinase-expressing hypothalamic nuclei. D:
coronal section diagram of glucokinase-expressing nuclei closer to the forebrain. MAN, medial amygdalar nucleus; PVN, paraventricular nucleus; pPVN,
parvocellular PVN; LH, lateral hypothalamus; VMN, ventromedial nucleus; DMN, dorsomedial nucleus; ARC, arcuate nucleus; AP, area postrema; NTS, nucleus
tractus solitarius; DMV, dorsal motor nucleus of the vagus; ROb, raphe obscurus; RPa, raphe pallidus; LV, lateral ventricle; chp, choroid plexus; 3V, third
ventricle; d3V, dorsal 3rd ventricle. cNTS, central nucleus tractus solitarius.
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Intracarotid infusion of glucose increases c-fos expression in
VMH neurons, a well-established marker of neuronal activa-
tion (58). Whereas insulin-induced hypoglycaemia (IIH) in-
creased glucokinase expression and neuronal activity in the
VMH (75), reduction of glucokinase mRNA by 90% in cul-
tured VMH neurons using RNA interference abolished all
demonstrable glucose-sensing ability (73). In a low-glucose
environment, pharmacological activation of glucokinase in-
creases neuronal activity in GE neurons and decreases that of
GI neurons, as demonstrated by changes in Ca2 oscillations
(73). These findings suggest that plasma glucose levels alter
neuronal activity via glucokinase in VMH neurons, with glu-
cokinase being the glucose sensor. In support of this, electro-
physiology studies have revealed that glucokinase inhibition
decreases GE neuronal activity, whereas it increases that of GI
neurons (42, 74, 167).
It is important to note that hexokinase I is also expressed in
VMH glucose-sensing neurons (75). Hexokinase I has a much
higher affinity for glucose (Km 1 mmol/l). However, unlike
glucokinase, its kinetic properties prevent it from modulating
its activity according to ambient glucose concentrations (129).
Therefore, in the VMH, hexokinase I appears to drive the
metabolism of glucose to maintain a constant supply of ATP,
regardless of fluctuations in extracellular glucose concentra-
tions, whereas glucokinase acts as a glucose sensor by bio-
chemically coupling glucose flux to cellular processes that may
be distinct from cellular ATP production (11, 129).
McCrimmon (98) describes VMH glucokinase as having a
pivotal role in inducing the CRR to hypoglycemia. This is
backed by the findings of Sanders et al. (141), who reported
that injections of the glucokinase inhibitor alloxan into the
third ventricle impaired the CRR to hypoglycaemia in rats.
Initial studies have focused on the VMH as a whole rather
than specifically examining the role of ARC and VMN glu-
cokinase in the CRR. The VMN is regarded as an important
hypothalamic glucose-sensing center, and glucokinase has
been implicated as the primary glucose sensor (Fig. 4) (73).
Indeed, hypoglycemia increased the sensitivity of glucose-
sensing neurons in parallel with an increase in glucokinase
mRNA within the VMN (88).
Stanley et al. (153) demonstrated colocalization of glucoki-
nase and growth hormone-releasing hormone (GHRH) in ARC
neurons. GHRH neurons mediate the secretion of growth
hormone (GH) (153), which is released during hypoglycemia
as part of the CRR (137). Although less important than imme-
diate sympathetic nervous system responses such as glucagon
and adrenaline release, GHRH release has been implicated in
the generation of the CRR and is part of the later neurohor-
monal CRR cascade (10, 55, 164). Because glucokinase activ-
ity leads to neurotransmitter secretion in other neurons (63), it
is possible that ARC glucokinase may induce GH release from
GHRH-expressing neurons in response to a decrease in ambi-
ent glucose levels (51). A direct link between glucokinase
activity and GH release has not been shown, however, and
Glucose
Glucose
Glucokinase
GLUT2/GLUT3
Glucose-6-phosphate
ATP
K+ X
KATP channel
ΔVm
Ca2+ channel
Ca2+
Ca2+
Cellular 
depolarisation
Insulin/Neurotransmitter 
release
Extra-cellular 
space
ATP Adenosine tri-phosphate
Ca2+ Calcium ion
Ca2+ channel Calcium channel
ΔVm Change in membrane voltage
GLUT2 Glucose Transporter 2
GLUT3 Glucose Transporter 3
K+ Potassium ion
KATP channel ATP-sensitive potassium channel
Fig. 2. Role of glucokinase in the peptide release mechanism of pancreatic -cells and glucose-excited neurons. Glucokinase activity leads to cellular
depolarization, followed by insulin secretion in pancreatic -cells or neurotransmitter release in glucose-excited neurons. As extracellular glucose concentrations
increase, glucose is taken up into the islet cell predominantly by glucose transporter 2 (GLUT2) (158) and into the neuron predominantly via GLUT3 glucose
transporters (160). Once in the cytosolic space, glucose is phosphorylated by glucokinase to form glucose 6-phosphate (95). Although this reaction consumes
adenosine triphosphate (ATP), the levels of ATP ultimately rise due to further glycolysis of glucose. The coupling of glucose entry with glycolysis and ATP
production allows the increase in ATP concentration to inhibit ATP-sensitive potassium (KATP) channels. This prevents the efflux of K ions. As a result K
ions accumulate within the neuron, and the membrane potential of the cell rises. The difference in membrane voltage triggers the influx of Ca2 ions through
voltage-gated Ca2 channels. Ca2 entry causes cellular depolarization, which in turn leads to an action potential (130). This proposed mechanism allows
glucokinase to function as a glucose sensor by coupling glucose availability with -cell and neuronal activity and insulin and neurotransmitter release (108).
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additional research is required to establish the role of glucoki-
nase in GH secretion.
Recurrent hypoglycemia is known to blunt the CRR to
subsequent hypoglycemic episodes (116, 118). Studies have
shown that antecedent IIH increases glucokinase mRNA ex-
pression in the VMH (42, 75, 118). This upregulation could
lead to a requirement for a lower glucose level in VMH
glucose-sensing neurons to initiate the CRR by increasing
glycolytic flux in the neurons regulating the CRR. Levin et al.
(88) reported that in vivo microinjection of the glucokinase
activator compound A diminished the CRR to acute hypogly-
cemia, whereas selective downregulation of VMH glucokinase
had the opposite effect. Therefore, by having a pivotal role in
glucose sensing, VMH glucokinase may act as regulator of the
CRR to hypoglycemia. The presence of VMH glucokinase
activity allows reductions in glucose to be sensed during
hypoglycemia and is important for the initiation of the CRR.
However, variations in the activity of glucokinase may alter the
glucose threshold at which the CRR to hypoglycemia is initi-
ated.
The mechanism behind the effects of VMH glucokinase on
the CRR is unknown. Pharmacological activation of KATP
channels in the VMH enhanced the CRR to hypoglycemia in
rats (99). KATP channels thus seem to play a role in glucose-
sensing neurons in the detection of hypoglycemia and in the
generation of the CRR. Because they are expressed in glucoki-
nase-expressing VMH neurons and are involved in the en-
zyme’s downstream signaling pathway (12, 63), KATP channels
may form part of the mechanism mediating hypothalamic
glucokinase’s effects on the pancreas. Supporting this, iVMH
administration of the KATP channel blocker glibenclamide
inhibited the secretion of glucagon and adrenaline in response
to both systemic hypoglycemia and central glucopenia (48).
This study suggests a link between the VMH and the pancreas,
which has also been postulated in other studies. For instance,
microinjection of the nonmetabolizable glucose analog 2-de-
oxyglucose into the VMH induced the release of glucagon,
adrenaline, and noradrenaline, and this response was blocked
by iVMH glucose infusion (23, 24). The CRR may be triggered
by the inhibition of VMH GABAergic neurons following the
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Glucose-6-phosphate
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space
ATP Adenosine tri-phosphate
ΔVm Change in membrane voltage
GLUT2 Glucose Transporter 2
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Neuronal 
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X
Fig. 3. Proposed mechanism by which glu-
cokinase activity leads to neuronal hyperpo-
larization and inhibits neurotransmitter re-
lease in glucose-inhibited neurons. As extra-
cellular glucose concentrations increase,
glucose is taken up into the islet cell predom-
inantly by GLUT2 (158) and into the neuron
predominantly via GLUT3 glucose transport-
ers (160). Once in the cytosolic space, glu-
cose is phosphorylated by glucokinase to
form glucose 6-phosphate (95). Although this
reaction consumes adenosine triphosphate
(ATP), the levels of ATP ultimately rise due
to further glycolysis of glucose. The coupling
of glucose entry with glycolysis and ATP
production allows the increase in ATP con-
centration to stimulate sodium potassium
ATPase (Na/K ATPase) pumps. For one
ATP molecule, each pump pumps three Na
ions out of the cell and enables the entry of
two K ions. This causes a decrease in mem-
brane voltage and results in hyperpolariza-
tion of the cell (80), ultimately leading to a
decrease in neuronal firing.
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feeding
VMN
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Fig. 4. Postulated roles of glucokinase in the
hypothalamus. Summary illustration describ-
ing the role of glucokinase in each of the
major hypothalamic nuclei expressing the glu-
cose sensor. PVN, paraventricular nucleus;
LH, lateral hypothalamus; VMN, ventrome-
dial nucleus; DMN, dorsomedial nucleus;
ARC, arcuate nucleus; CRR, counterregula-
tory response.
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decrease of hypothalamic glucose levels (16–17, 30, 177),
suggesting that glucokinase in GE neurons mediates the CRR.
Nitric oxide has also been implicated in the generation of the
response, but not in GABAergic neurons (50). The VMH is
likely to be linked to the periphery via sympathetic and
parasympathetic connections, both of which innervate pancre-
atic -cells (4). These connections could occur via the brain-
stem, which is known to relay hypothalamic autonomic signals
to the gut (4). Sympathetic nerve stimulation resulted in glu-
cagon secretion, and this response was abolished by the -ad-
renergic receptor blocker phentolamine (81). Hence, the VMH
may cause glucagon release through splanchnic sympathetic
innervation of pancreatic -cells, perhaps by releasing adren-
aline and noradrenaline acting on 2- and 2-adrenergic recep-
tors located on the -cells (17, 31, 82, 154–156). Vagal
cholinergic pathways, which form part of the parasympathetic
nervous system, have also been implicated in the autonomic
regulation of glucagon secretion, as muscarinic M3 receptor
activation resulted in glucagon release (165). Acetylcholine
may also act directly on adrenal cells to induce adrenaline
release (116).
Glucokinase in the medial amygdalar nucleus contributes to
initiation of the counterregulatory response. The presence of
glucose-sensing neurons in the MAN has been demonstrated as
subcutaneous injections of 2-DG-increased c-Fos activity (41).
A role in the CRR has been postulated as stimulation of the
amygdala-increased glucagon secretion, whereas lesions had
the opposite effect (71). Glucokinase is expressed in the MAN
and may be responsible for the detection of hypoglycemia and
the initiation of the CRR (175). Zhou et al. (175) report that
lesions in the MAN suppressed whereas 2-DG infusion ampli-
fied the CRR/IIH in vivo. In addition, MAN glucoprivation
during mild systemic hypoglycaemia amplified the CRR. How-
ever, local glucoprivation (caused by injection of 2-DG) in the
MAN alone is insufficient to generate a counterregulatory
hormone response, suggesting that MAN glucose sensing plays
only a contributory role to other regions involved in CRR, such
as the VMH.
The signaling pathways between the MAN and the gut are
poorly understood. They may involve the vagus nerve, as
studies have shown that the MAN projects directly to the NTS
and DMV, which are known to relay signals from the forebrain
to the gut via vagal efferents, although this has been shown
mostly in the central nucleus of the amygdala rather than the
MAN (162, 163, 174). The mechanism behind the effect of
MAN glucokinase on the CRR has not been explored.
Glucokinase in the Dorsal Vagal Complex: Glucose Sensor
Roles but Uncertain Function
The DVC of the brainstem is a large structure containing the
NTS, AP, and DMV, all of which possess glucose-sensing
properties. It is considered to be an important center for
glucose homeostasis and has been associated with the CRR
(132, 157).
Each of the DVC nuclei expresses low levels of glucokinase
(5, 42). IIH increased glucokinase mRNA expression in the
DVC (53), whereas prolonged hyperglycemia in streptozoto-
cin-induced diabetic rats decreased it (59). This suggests a role
for glucokinase in glucose sensing. Whole cell patch clamp
recordings testing the neuronal response to hypoglycemia
showed that glucokinase is expressed in both GE and GI
neurons (14); however, further evidence supporting this claim
is sparse, and additional research is needed to determine its
exact role in the DVC.
Glucokinase in the area postrema. The AP has an incom-
plete blood-brain barrier (BBB), which enables glucose to
diffuse into the DVC (170). Therefore, it may play a role in
glucose sensing in this region. Glucose-sensing properties have
been discovered in the AP (2, 131), and glucose-sensitive
neurons of the AP were shown to be both stimulated and
inhibited by varying concentrations of glucose (1, 52). Due to
its glucose-sensing properties, the AP may be involved in
glucose homeostasis (3).
Contreras et al. (36) suggested a role for the AP in energy
homeostasis, as lesions to this brain region induced hypophagia
and rapid body weight loss in rats. They described the possi-
bility of a complementary role between the AP and the NTS in
the regulation of caloric intake potentially mediated by glu-
cokinase. However, no work has been conducted to confirm
these authors’ claims, and the role of glucokinase in the AP
remains unclear.
Glucokinase in the nucleus tractus solitarius. The existence
of glucose-sensitive neurons in the NTS has been demonstrated
(2, 173). For instance, a glucoprivic feeding response induced
by the administration of 2-deoxyglucose and 5-thioglucose to
the fourth ventricle was lost following lesioning of the NTS,
suggesting that this nucleus possesses glucose-sensing proper-
ties (104, 133, 149). Whole cell and on-cell patch clamp
recordings have demonstrated both increased and decreased
neuronal excitability in the NTS in response to an elevation in
environmental glucose, suggesting the presence of both GE
and GI neurons (25). Evidence supports the presence of
GLUT2 and KATP channels (37, 158), two glucose-sensing
components, in the NTS. GLUT2 neurons have been linked
with the CRR, as they are activated by hypoglycaemia and
contribute to glucagon secretion (84).
Reverse transcription-polymerase chain reaction (RT-
PCR) suggests low expression levels of glucokinase in the
NTS (42). In situ hybridization studies did not detect its
presence within this nucleus, however (92), perhaps because
in situ hybridization may not be sensitive enough to detect
the low levels of glucokinase present in the NTS. Very little
research has been done to link glucokinase to the glucose-
sensing machinery of the NTS, and its role in this nucleus
remains unexplored.
Glucokinase in the dorsal motor nucleus of the vagus. The
DMV contains glucose-sensitive neurons (2). Along with the
NTS, it may also be part of a hypothalamus-brainstem-liver
circuit regulating liver gluconeogenesis. Pocai and colleagues
(125, 126) have suggested that hypothalamic lipid sensing
triggers a signal to the NTS, possibly via the activation of KATP
channels. It is then transferred to the DMV, which relays it to
the liver via a vagal efferent pathway. The DMV thus appears
to play a role in the regulation of peripheral glucose homeo-
stasis.
Low levels of glucokinase are expressed in the DMV (92);
however, its physiological role in this nucleus has not been
investigated. So far, no evidence has implicated it in the
DMV’s glucose-sensing mechanism.
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GLUCOKINASE AND THE REGULATION OF APPETITE
The relationship between glucose sensing and feeding be-
havior has been postulated following earlier work demonstrat-
ing the colocalization of the receptor for the anorexigenic
hormone GLP-1, glucokinase, and glucose transporters in brain
areas controlling feeding behavior and containing glucose-
sensing neurons (6).
Although for some time direct evidence has been lacking,
recent data provide strong evidence for the role of glucokinase
and neuronal glucose sensing in appetite. Hypoglycemic and
euglycemic clamps have shown an influence of glucose levels
on appetite, particularly for high-calorie foods (121). Rodent
data have highlighted a role for hypothalamic glucose sensing
in appetite regulation (63). In humans, differential patterns of
neuronal activation can result from changes in glucose concen-
trations and alter food-seeking behaviour (121). Increasing
evidence linking glucokinase in the ARC and LH to the
regulation of appetite will be discussed in this section.
Glucokinase in the Arcuate Nucleus: Taste-Independent
Promoter of Glucose-Rich Foods
Depletion of VMH glucokinase did not change spontaneous
feeding, body weight, or glucose tolerance, but it caused a
reduction in glucoprivic feeding, thus suggesting a role for
VMH glucokinase in this process (43).
The VMH contains the ARC, a nucleus that has been
implicated in the regulation of appetite since it contains both
the orexigenic neuropeptide Y (NPY) and agouti-related pep-
tide (AgRP) neurons and anorexigenic proopiomelanocortin
(POMC) and cocaine- and amphetamine-regulated transcript
neurons (35, 57, 72).
Glucokinase is expressed at relatively high levels in the
ARC (42, 92, 113) and in POMC and NPY neurons (66, 109,
123). The medial ARC is adjacent to the median eminence. The
capillaries of this circumventricular organ form fenestrations
during times of low glucose availability (106, 124) to enable
the movement of glucose from the bloodstream into the ARC
to maintain a steady nutrient supply when diffusion of glucose
via GLUT1, GLUT3, and GLUT4 transporters present in the
BBB (112) is not sufficient. The ARC appears to be an
important glucose-sensing center, as it modulates glucose entry
depending on plasma glucose concentrations.
Guillod-Maximin et al. (58) showed that an intracarotid injec-
tion of glucose triggered a significant increase in the number of
Fos-positive nuclei, indicative of neuronal activation, in the ARC
compared with rats injected with vehicle, suggesting that increas-
ing plasma glucose activates ARC neurons. Alterations in periph-
eral glucose levels modulate glucokinase expression. Indeed,
fasting, a state associated with lower glucose levels and increased
motivation to consume food, increases ARC glucokinase levels
(63, 75, 142). Conversely, ARC glucokinase activity decreases in
streptozotocin-induced diabetic rats, presumably because of the
prolonged hyperglycemia (113). Therefore, ARC glucokinase
may be expressed in GI neurons and play a role in appetite
regulation by allowing the ARC to respond to changes in glucose
and alter appetite.
We have recently found evidence suggesting that glucoki-
nase in the ARC regulates energy homeostasis by using phar-
macological and genetic approaches to specifically increase
glucokinase activity in the ARC of rodents (63). Upregulated
ARC glucokinase activity increased chow intake and specifi-
cally increased glucose intake Wistar in rats. Conversely, a
reduction in ARC glucokinase activity decreased consumption
of these foods. Interestingly, only glucose consumption was
affected when both glucose and chow were available. Fructose
intake remained unchanged (63), suggesting that ARC glucoki-
nase controls glucose appetite via a taste-independent mecha-
nism possibly analogous to that in Drosophila (44). That work
further provided a mechanism involving KATP channels and
changes in glucose-stimulated NPY release in mediating the
effects of glucokinase. Previous works support the involve-
ment of glucokinase in NPY release as well as the colocaliza-
tion of glucokinase and KATP in NPY-containing neurons (92,
161). Alterations in NPY expression have also been shown
following the manipulation of KATP channels (78, 122).
The mechanism leading to increased glucose intake follow-
ing glucokinase activation may include the PVN and DMN.
ARC NPY neurons project to the parvocellular division of the
PVN (pPVN) and to the DMN. These projections were shown
to influence carbohydrate intake, as a positive correlation was
shown between carbohydrate ingestion and NPY levels in the
ARC, pPVN, and DMN (70, 79). NPY may stimulate feeding
by activating Y1 and Y5 receptors in these hypothalamic nuclei
(63). The pPVN may in turn relay the signal to the brainstem,
leading to the release of orexigenic peptides in the gut via vagal
efferents through a well-known forebrain-hindbrain-gut path-
way (20, 144). However, this pathway is more commonly
associated with satiety signaling (18–22). Another possible
mechanism involves the paraventricular thalamic nucleus
(PVT). ARC NPY neurons project to the PVT, possibly via the
LHA (47, 77). A study showed that PVT neurons receiving
NPY terminals from the ARC provide divergent axon collat-
erals to the nucleus accumbens (NA) (86), suggesting that the
promoting effects of ARC glucokinase on glucose intake may
be driven by reward signals. However, this seems unlikely, as
the intake of fructose, which is more associated with a hedonic
response (145), was unaffected by changes in glucokinase
expression (63). Further investigation is required to shed light
on the mechanism responsible for the effects of ARC glucoki-
nase on the appetite for glucose-rich foods.
Several studies do not support a role for ARC glucokinase in
appetite regulation. VMH knockdown of glucokinase activity
with alloxan and short-hairpin RNA, delivered via an adeno-
viral vector, did not change appetite regulation at 24 h and 14
days, respectively (43). Limitations of this study included use
of a cytotoxic glucose analog (140) and immune responses in
relation to adenoviral gene transfer (76). Intracerebroventricu-
lar (icv) administration of a nonspecific glucokinase inhibitor,
glucosamine, increased glucoprivic feeding and stimulated
hypothalamic NPY secretion, which directly contradicts our
findings (176). In addition, Levin et al. (88) observed no
changes in food intake when VMH glucokinase activity was
pharmacologically altered. However, these studies did not
target the ARC exclusively, so the pharmacological agents in
the hypothalamus may have had confounding effects.
Glucokinase in the Lateral Hypothalamic Area: Mediation of
Glucoprivic Feeding?
The glucose-sensing center of the LH is traditionally divided
into two sections, the lateral hypothalamic area (LHA) and the
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perifornical area. Both of these areas possess glucose-sensing
properties since increases in peripheral glucose concentrations
induced c-fos immunoreactivity (153), and orexin-expressing
neurons within them are activated by hypoglycemia (26, 28,
105).
Glucokinase mRNA is moderately expressed in the LHA of
rats (92, 113) and rainbow trout (127). Conversely, it has not
been detected in neurons of the perifornical area. Glucose
sensing in this area is likely to utilize a mechanism not
involving glucokinase, and thus the rest of this section will
focus on the LHA.
The glucose-sensing role of LHA neurons was demonstrated
when cell firing was altered by varying glucose concentrations.
One study demonstrated the number of action potentials of the
glucose-sensitive neurons (forming 30% of LHA cells) in-
creased following a reduction in glucose concentration. Rais-
ing glucose levels had the opposite effect, suggesting that LHA
glucose-responsive cells are GI in type. Silver and Erecinska
(147) proposed a “glucokinase-type” enzyme as a possible
mechanism for the detection of changes in glucose concentra-
tion. A different study demonstrated changes in the levels of
Ca2 intracellular LHA neurons in response to glucose (107).
These studies support the work of Stanley et al. (153), who
used intraperitoneal 2-deoxy-D-glucose (2-DG) injections to
mimic hypoglycemia to assess neuronal activation in glucoki-
nase-expressing cells stained with yellow fluorescent protein.
2-DG induced a significant increase in c-fos immunoreactivity
in yellow fluorescent protein-immunopositive neurons in the
LH (153). Although unspecified by the authors, immunoreac-
tivity is likely to have occurred in the LHA, as glucokinase is
not expressed in the perifornical area. The c-fos response to
hypoglycemia suggests that glucokinase-expressing cells in
this area play a role in the neural pathways activated by low
glucose.
LHA glucokinase may play a role in glucose-sensing, as its
activity in rat LH slices decreased upon exposure to increasing
glucose concentrations (142). Moreover, its activity in the
LHA was increased during IIH (33), suggesting that glucoki-
nase may be expressed in GI neurons. Zhou et al. (176)
investigated its role via icv injections of its inhibitor gluco-
samine. They reported that glucosamine stimulated feeding and
induced c-fos activation in the LHA. Glucosamine-stimulated
c-fos was detected within the appetite-stimulating orexin neu-
rons. Hence, glucokinase within this neuronal population may
play a role in the sensing of hypoglycemia and mediating of
glucoprivic feeding.
LHA glucokinase may induce glucoprivic feeding by stim-
ulating a hedonic response, implying a role in food reward. A
high density of orexinergic neuronal projections from the LH
terminates in the PVT, which acts as a relay center to the NA
(86, 94). This circuit could be powered by cholinergic interneu-
rons via muscarinic receptor activation to convey information
regarding energy balance to output neurons and may involve
enkephalin, among other peptides (77). The majority of orexi-
genic projections to the PVT originate in the perifornical area
of the LH rather than the glucokinase-expressing LHA (86);
however, orexinergic connections between the LHA and the
PVT also exist (94). LHA glucokinase may also mediate
glucoprivic feeding through direct connections between the
LHA and the gut, as diet restriction induced neuronal activa-
tion of the LHA in mice (143). This brain-gut connection
appears to occur via the vagus nerve and may be bidirectional,
as vagotomy impaired LHA neuronal activation induced by
intragastric infusions of various glutamate-containing solutions
(38, 171).
Others dispute the role of glucokinase in glucose sensing
within LHA orexin neurons. They demonstrated that orexin
cell glucose sensing is not affected by glucokinase inhibitors
and presented evidence that glucokinase is not expressed in
orexin neurons (56). Evidence supporting the involvement of
glucokinase in LHA glucose sensing is controversial, and
additional investigation is required to determine its function in
this region.
GLUCOKINASE IN OTHER CNS REGIONS
The presence of glucose-sensing neurons in parvocellular
neurons of the PVN has been demonstrated (102). Glucoki-
nase mRNA has been detected in the PVN as well as its
regulatory protein (7), although its role in this hypothalamic
nucleus has not been clearly identified. Glucokinase expres-
sion is found in oxytocin and vasopressin neurons of the
supraoptic nucleus located in the PVN, where it has been
postulated as a glucose sensor. Indeed, increases in glucose
stimulated oxytocin and vasopressin release during a hypo-
thalamic explant study in a glucokinase-dependent manner.
It also increased cellular Ca2 levels (148, 150), indicating
that glucokinase-expressing neurons in the SON are GE in
type. The glucokinase-induced release of oxytocin is con-
sistent with the PVN’s role in satiety, as PVN oxytocin
neurons project to the NTS to induce CCK release (18).
However, the role of glucokinase in the PVN has not been
greatly examined, and further research is needed to deter-
mine whether it is involved in satiety signaling.
Low levels of glucokinase are also expressed in other brain
regions. These include the cerebral cortex, cerebellum, lateral
habenula, bed nucleus stria terminalis, inferior olive, retrochi-
asmatic and medial preoptic areas, and the thalamic posterior
paraventricular, interpeduncular, oculomotor, and anterior ol-
factory nuclei (5, 7, 34, 85, 92, 135). Glucokinase expression
has also been found in several raphe nuclei in the brainstem,
including the raphe obscurus, raphe pallidus, raphe magnus,
and raphe pontis (93). However, its role in these neuronal areas
is unknown. The low levels of the enzyme suggest that its
function may be of lesser importance compared with other
regions discussed.
CLINICAL IMPLICATIONS: CAN TARGETING GLUCOKINASE
HELP IN DIABETES AND OBESITY?
Glucose Homeostasis and Diabetes
The rising prevalence of T2DM, characterized by high
plasma glucose levels due to increased glucose production and
an impaired response to insulin, is a considerable health and
socioeconomic problem prompting the development of new
treatments. In 2014, 387 million individuals were affected by
diabetes worldwide, a figure expected to nearly double by 2035
(66a). Treatments have focused on the peripheral organs such
as the pancreas and liver. Targeting the brain may provide a
novel mechanism to stimulate insulin secretion in T2DM
patients (119, 156). Glucokinase activity in the hypothalamus
may be involved in peripheral insulin secretion, as icv admin-
Review
E49THE ROLE OF NEURONAL GLUCOKINASE
AJP-Endocrinol Metab • doi:10.1152/ajpendo.00034.2016 • www.ajpendo.org
 by guest on July 11, 2016
http://ajpendo.physiology.org/
D
ow
nloaded from
 
istration of glucokinase inhibitors reduced GSIS in rats (119).
Theoretically, augmenting its activity specifically in this region
may hence boost insulin secretion from -cells. The effects of
increased glucokinase activity via pharmacological manipula-
tion have been studied in the VMN and ARC (63, 73). Given
the close functional relationship between glucokinase and
KATP channels, sulfonylureas may also augment insulin secre-
tion via the brain; however, this remains to be tested.
In rodents, extracellular glucose levels in neuronal glucose-
sensing centers such as the VMH typically vary between 0.5
and 2.5 mM and remain 0.5 mM in other brain areas (39,
167). The neuroendocrine form of glucokinase is most sensi-
tive to glucose within this concentration window (73). A study
in rats has shown that CSF glucose levels do not rise above 4.5
mM (146). Levels of CSF glucose in diabetes are presumed to
be higher than in healthy humans, although this has not been
properly established; however, a similar limit in glucose trans-
port once a certain threshold has been reached is probable, as
humans and rodents have similar glycaemic profiles (169).
Therefore, CNS glucose levels in diabetes are likely to be
lower than in the periphery.
Hypoglycemia unawareness is a challenge in the manage-
ment of diabetes (9). It results from abnormalities in glu-
cose-sensing leading to defective CRR to IIH (98). Enhanc-
ing the CRR by restoring glucose-sensing pathways may
rectify hypoglycemia unawareness by contributing to the
prevention of IIH due to insulin treatment. Intracerebroven-
ticular infusion of a low-dose hexokinase inhibitor, gluco-
samine, boosted feeding responses to glucoprivation in rats
with impaired CRR (120). Limitations of this study in
applying these findings to glucose sensing and glucokinase
were discussed earlier; however, they suggest a potential for
glucose-sensing modulation in enhancing orexigenic signal-
ing during hypoglycaemia. A recent approach via a mech-
anism downstream to glucokinase utilized the KATP channel
activator diazoxide to improve CRR to IIH in humans (54).
Targeting glucokinase in the VMH or MAN may provide an
alternative strategy to treat this difficult disorder.
Appetite and Obesity
The recent rise in obesity is a growing concern. The World
Health Organization estimates that in 2014 more than 1.9
billion adults were overweight, of which 600 million were
obese, fueling the pressing need for treatments (168). Obesity
is an important risk factor for cardiovascular diseases and
metabolic disorders such as T2DM (65).
We recently provided evidence that ARC glucokinase reg-
ulates feeding and preference for glucose-rich foods (63). Low
glucose levels, which lead to food-seeking behavior, have been
shown to enhance glucokinase expression (75). Glucokinase
activation promotes NPY secretion in the ARC, which may
drive food intake (63). An inhibitor targeting glucokinase
specifically in this region could potentially reduce appetite.
Supporting this, the anorexigenic peptide GLP-1-(7–36),
which has the opposite effect of NPY on satiety, significantly
reduced cerebral glucose metabolism in human hypothalamus
and brainstem. GLP-1-(7–36) administration may impair glu-
cose transport by reducing GLUT2 expression and/or glucose
phosphorylation by glucokinase. These components are colo-
calized in hypothalamic neurons, suggesting that a glucose-
sensing system may be involved in the transduction of satiety
signals (5). The beneficial effects of GLP-1-(7–36) on glucose
metabolism support a potential role for ARC glucokinase
inhibitors in the regulation of appetite. In vivo studies are
required to determine whether such agents can bypass the BBB
and act directly in the hypothalamus.
CONCLUDING REMARKS AND FUTURE PERSPECTIVES
Glucokinase is critical for neuronal glucose sensing and
energy homeostasis. Earlier work has demonstrated an impor-
tant role for this neuronal enzyme in the hypothalamus. More
recent studies have supported this but also extended its impor-
tance beyond the hypothalamic region. As suggested in this
review, there are implications from these studies for the devel-
opment of effective drugs against the increasingly prevalent
obesity and T2DM.
It is important to note that although glucose is an impor-
tant energy signal, other metabolic signals also play a role in
energy homeostasis (87). Insulin can alter neuronal depo-
larization (152) by acting on KATP channels (167) or via the
insulin-sensitive GLUT4 (74). Hypothalamic glucose-sens-
ing neurons are also sensitive to changes in fatty acid (166),
lactate (151), or ketone body (103) levels. It is unclear
whether glucokinase plays a role in mediating the response
to these various signals.
Research identifying the role of neuronal glucokinase has
some limitations. In some instances, manipulating plasma
glucose levels may alter glycemia outside physiological levels.
The findings thus may not be representative of glucokinase’s
role in normal conditions. In addition, quantification of glu-
cokinase expression in the brain does not allow measurement
of its neuronal activity, and its presence is not necessarily
indicative of its involvement in any neuronal processes. An-
other obstacle is targeting the appropriate brain region with
pharmacological agents or viral vectors in vivo. Intranuclear
injections require immense precision, and their accuracy often
cannot be verified until the end of the study.
Much remains to be learned about the role of neuronal
glucokinase. Potential avenues to explore include identifying
downstream targets for glucokinase’s effect on glucose appe-
tite, obesity, and glucose homeostasis, exploring its role in
regions outside the hypothalamus, and characterizing the glu-
cose-brain-islet pathway causing GSIS. Finally, recent works
suggest possible targets for diabetes and obesity treatments.
They also prompt review of possible off-target effects from
glucokinase activators currently in clinical trials that may
promote appetite and weight gain. The influence of nonneuro-
nal cells such as tanycytes, not discussed in this review, in
glucose sensing requires further characterization. Glucokinase
regulatory protein (GKRP) expressed in rat (136) and human
(134) brains can interact with glucokinase. Although further
investigation is needed to detail the relationship between glu-
cokinase activity, GKRP, and glucose sensing, it raises the
potential of influencing glucokinase activity and glucose sens-
ing via alternative mechanisms.
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